4.6 Editorial Material

MULTIPLE SCLEROSIS Oral laquinimod for MS-bringing the brain into focus

期刊

NATURE REVIEWS NEUROLOGY
卷 9, 期 12, 页码 664-665

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2013.234

关键词

-

向作者/读者索取更多资源

Currently approved multiple sclerosis (MS) treatments mainly target the peripheral immune system, thereby reducing relapse rates and MRI markers of inflammation. A recent phase III trial indicates that laquinimod, a new orally active immunomodulator, has a CNS-intrinsic mode of action that is independent of effects on the peripheral immune response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据